miR-132 Inhibitor CDR132L Misses Primary Endpoint in Post-MI Heart Failure Trial
A phase 2 trial of the microRNA-132 inhibitor CDR132L showed safety but no significant improvement in cardiac remodeling after heart attack.
Summary
CDR132L is a synthetic antisense oligonucleotide designed to block microRNA-132, a key driver of harmful changes in heart structure after a heart attack. In the multinational HF-REVERT trial, 294 patients with reduced heart function following a recent heart attack were randomized to receive CDR132L or placebo on top of standard therapy. After six months, the primary measure of cardiac remodeling — left ventricular end-systolic volume index — improved in all groups but did not differ significantly between CDR132L doses and placebo. Secondary heart function measures also showed no significant differences. Importantly, the drug appeared safe with no organ toxicity. Exploratory analyses hinted at potential benefit in patients with the most severe baseline remodeling, suggesting future trials in chronic heart failure may be warranted.
Detailed Summary
Heart failure following a myocardial infarction (MI) remains a leading cause of death and disability worldwide. After an MI, the heart undergoes adverse remodeling — structural changes that progressively weaken cardiac function. MicroRNA-132 (miR-132) has been identified as a central molecular regulator of this process, making it an attractive therapeutic target.
The HF-REVERT trial was a multinational, randomized, double-blind, placebo-controlled phase 2 study evaluating CDR132L, a synthetic antisense oligonucleotide that inhibits miR-132. A total of 294 patients with recent MI (within 3–14 days) and reduced left ventricular ejection fraction were randomized to receive CDR132L at 5 mg/kg, CDR132L at 10 mg/kg, or placebo. Doses were administered intravenously three times at four-week intervals alongside guideline-directed medical therapy.
The primary endpoint — percentage change in LV end-systolic volume index at six months — improved across all three groups but did not significantly differ between CDR132L doses and placebo. Secondary endpoints including LV ejection fraction, global longitudinal strain, and NT-proBNP also showed no statistically significant treatment differences. However, CDR132L demonstrated a favorable safety profile with no hepatic, renal, hematologic, or cardiac toxicity signals detected.
Prespecified exploratory analyses identified a subgroup of patients with more advanced adverse remodeling at baseline who appeared to derive potential benefit from CDR132L treatment. This finding, while hypothesis-generating, supports further investigation of the drug, possibly in the chronic heart failure setting where adverse remodeling is more established.
The trial's negative primary result may reflect the acute post-MI context, where spontaneous recovery is substantial. Future trials targeting patients with chronic, progressive heart failure — where standard therapies have plateaued — may better capture CDR132L's therapeutic potential. The RNA-targeting approach remains scientifically compelling.
Key Findings
- CDR132L did not significantly improve LV end-systolic volume index versus placebo at 6 months.
- All groups showed improvement in cardiac remodeling, suggesting strong background recovery post-MI.
- No hepatic, renal, hematologic, or cardiac toxicity was detected at either dose tested.
- Exploratory analyses suggest potential benefit in patients with the most severe baseline remodeling.
- Findings support evaluating CDR132L in chronic heart failure rather than acute post-MI settings.
Methodology
HF-REVERT was a multinational, randomized, double-blind, placebo-controlled phase 2 trial (NCT05350969). A total of 294 patients were randomized within 3–14 days of MI; 280 received at least one dose and formed the modified intention-to-treat population. Three intravenous doses were administered at 4-week intervals at two dose levels (5 and 10 mg/kg) alongside standard guideline-directed therapy.
Study Limitations
The full manuscript is not open access; this summary is based on the abstract only and may omit important subgroup data, safety details, or exploratory analyses. The acute post-MI setting may have been suboptimal for detecting treatment effects due to high background spontaneous recovery. The trial enrolled predominantly male patients (87.5%), limiting generalizability to women.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.